26 October 2022 in Open Biology
MCMaria Gabriella Caporaso
Lysosomal storage diseases (LSDs) comprise a group of inherited monogenic disorders characterized by lysosomal dysfunctions due to undegraded substrate accumulation. They are caused by a deficiency in specific lysosomal hydrolases involved in cellular catabolism, or non-enzymatic proteins essential for normal lysosomal functions. In LSDs, the lack of degradation of the accumulated substrate and its lysosomal storage impairs lysosome functions resulting in the perturbation of cellular homeostasis and, in turn, the damage of multiple organ systems. A substantial number of studies on the pathogenesis of LSDs has highlighted how the accumulation of lysosomal substrates is only the first event of a cascade of processes including the accumulation of secondary metabolites and the impairment of cellular trafficking, cell signalling, autophagic flux, mitochondria functionality and calcium homeostasis, that significantly contribute to the onset and progression of these diseases. Emerging studies on lysosomal biology have described the fundamental roles of these organelles in a variety of physiological functions and pathological conditions beyond their canonical activity in cellular waste clearance. Here, we discuss recent advances in the knowledge of cellular and molecular mechanisms linking lysosomal positioning and trafficking to LSDs.
15 February 1996 in Physics Letters B
Multifragment disintegration has been measured with a high efficiency detection system for the reaction Au + Au at E/A = 35 MeV. From the event shape analysis and the comparison with the predictions of a many-body trajectories calculation the data, for central collisions, are compatible with a fast emission from a unique fragment source.
1 August 1995 in Physical Review C
Intermediate-mass-fragment emission has been studied in central E/A=30 MeV Cu reactions. The measured fragment multiplicities, reduced-velocity correlation functions, and emission velocities have been compared with schematic three-body trajectory calculations and with three statistical models with input based upon a dynamical BNV code. The statistical models which include expansion either explicitly or implicitly are able to generate a sufficient number of fragments. The three-body trajectory calculations indicate a mean emission time of ≊200 fm/c, consistent with sequential decay. Dynamical expanding-emitting source calculations predict a similar time scale for fragment emission and give satisfactory agreement with the experimental correlation functions if the experimental angular distributions are incorporated into the model. The Berlin multifragmentation model gives good agreement with the experimental charge distributions, and, depending upon the choice of radius parameter, can provide agreement with either the correlation functions or the fragment emission velocities, but not with both simultaneously. Although an overall good agreement is obtained in the statistical model comparisons, even in the most violent collisions the angular distributions and fragment emission velocities are incompatible with completely equilibrated decay from a single source.
23 April 2002 in Physical Review C
A good quality scaling of the cluster size distributions is obtained for the lattice gas model using the Fisher’s ansatz for the scaling function. This scaling identifies a pseudocritical line in the phase diagram of the model that spans the whole (subcritical to supercritical) density range. The independent cluster hypothesis of the Fisher approach is shown to describe correctly the thermodynamics of the lattice only far away from the critical point.
27 March 2023 in Human Molecular Genetics
Conformational diseases, such as Alzheimer, Parkinson and Huntington diseases, are part of a common class of neurological disorders characterized by the aggregation and progressive accumulation of proteins bearing aberrant conformations. Huntington disease (HD) has autosomal dominant inheritance and is caused by mutations leading to an abnormal expansion in the polyglutamine (polyQ) tract of the huntingtin (HTT) protein, leading to the formation of HTT inclusion bodies in neurons of affected patients. Interestingly, recent experimental evidence is challenging the conventional view by which the disease pathogenesis is solely a consequence of the intracellular accumulation of mutant protein aggregates. These studies reveal that transcellular transfer of mutated huntingtin protein is able to seed oligomers involving even the wild-type (WT) forms of the protein. To date, there is still no successful strategy to treat HD. Here, we describe a novel functional role for the HSPB1-p62/SQSTM1 complex, which acts as a cargo loading platform, allowing the unconventional secretion of mutant HTT by extracellular vesicles. HSPB1 interacts preferentially with polyQ-expanded HTT compared with the WT protein and affects its aggregation. Furthermore, HSPB1 levels correlate with the rate of mutant HTT secretion, which is controlled by the activity of the PI3K/AKT/mTOR signalling pathway. Finally, we show that these HTT-containing vesicular structures are biologically active and able to be internalized by recipient cells, therefore providing an additional mechanism to explain the prion-like spreading properties of mutant HTT. These findings might also have implications for the turn-over of other disease-associated, aggregation-prone proteins.